Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celsion Initiates First International Licensing Deal With Japan’s Yakult For Liver Cancer Drug ThermoDox

This article was originally published in PharmAsia News

Executive Summary

TOKYO -Yakult Honsha Co. of Tokyo and Celsion of Columbia, Md., announced a licensing agreement for Celsion's liver cancer drug ThermoDox, marking Celsion's first international licensing deal
Advertisement

Related Content

Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.
Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.
Celsion Signs Licensing Agreement With Japanese Yakult Honsha For Liver Cancer Agent ThermoDox
Celsion Signs Licensing Agreement With Japanese Yakult Honsha For Liver Cancer Agent ThermoDox
MHLW To Erase Drug Lag By 2011 And Oppose Reference Price System
Advertisement
UsernamePublicRestriction

Register

SC069359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel